The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy
Open accessAbstract
Systemic sclerosis (SSc) is a complex and incompletely understood disease associated with fibrosis in multiple organs. Recent findings identify transforming growth factor-ß (TGF-ß), Wnt ligands, toll-like receptor-mediated signaling, hypoxia, type I interferon, type 2 immune responses and mechanical stress as extracellular cues that modulate fibroblast function and differentiation, and as potential targets for therapy. Moreover, fibrillin-1 has a major role in storing and regulating the bioavailability of TGF-ß and other cytokines, and fibrillin-1 mutations are implicated in a congenital form of scleroderma called stiff skin syndrome. Fibrosis is due not only to the activation of tissue-resident fibroblasts and their transdifferentiation into myofibroblasts, but also the differentiation of bone marrow-derived fibrocytes, and transition of endothelial and epithelial cells, pericytes and adipocytes into activated mesenchymal cells. These responses are modulated by signaling mediators and microRNAs that amplify or inhibit TGF-ß and Wnt signaling. Gain-of-function and loss-of-function abnormalities of these mediators may account for the characteristic activated phenotype of SSc fibroblasts. The nuclear orphan receptor PPAR-γ plays a particularly important role in limiting the duration and intensity of fibroblast activation and differentiation, and impaired PPAR-γ expression or function in SSc may underlie the uncontrolled progression of fibrosis. Identifying the perturbations in signaling pathways, mediators and differentiation programs that are responsible for SSc tissue damage allows their selective targeting. This in turn opens the door for therapies utilizing novel compounds, or drug repurposing by innovative uses of already-approved drugs. In view of the heterogeneous clinical presentation and unpredictable course of SSc, as well as its complex pathogenesis, only robust clinical trials incorporating the judicious application of biomarkers will be able to clarify the clinical utility of these innovative approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Higgins, D. F., Kimura, K., Bernhardt, W. M., Shrimanker, N., Akai, Y., Hohenstein, B., Saito, Y., Johnson, R. S., Kretzler, M., Cohen, C. D., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30487 · Cited by 976
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Aberrant Wnt/β-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis
Chilosi, M., Poletti, V., Zamò, A., Lestani, M., Montagna, L., Piccoli, P., Pedron, S., Bertaso, M., Scarpa, A., Murer, B., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64282-4 · Cited by 708
Königshoff, M., Kramer, M., Balsara, N., Wilhelm, J., Amarie, O. V., Jahn, A., Rose, F., Fink, L., Seeger, W., Schaefer, L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci33950 · Cited by 558
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Hair Follicle Stem Cell-Specific PPARγ Deletion Causes Scarring Alopecia
Karnik, P., Tekeste, Z., McCormick, T. S., Gilliam, A. C., Price, V. H., Cooper, K. D., & Mirmirani, P. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.369 · Cited by 321
Asano, Y., Ihn, H., Yamane, K., Jinnin, M., Mimura, Y., & Tamaki, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7708 · Cited by 231
Connective tissue synthesis by scleroderma skin fibroblasts in cell culture
Leroy, E. C. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.135.6.1351 · Cited by 201
Ghosh, A. K., Bhattacharyya, S., Lakos, G., Chen, S., Mori, Y., & Varga, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20104 · Cited by 201
Self-citation
Cited by
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Armulik, A., Genové, G., & Betsholtz, C. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.001 · Cited by 2,653
“The role of pericytes asmyofibroblast precursors is suggested by studies of fibrogenesis in the liver (Fabris and Strazzabosco, 2011), kidney (Schrimpf and Duffield, 2011), and systemic sclerosis (SSc) (Mahoney et al., 2011; Wei et al., 2011).”
BackgroundRecent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Self-citationRole of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders
Piera-Velazquez, S., Li, Z., & Jimenez, S. A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.001 · Cited by 580
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities
Bhattacharyya, S., Wei, J., & Varga, J. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.149 · Cited by 381
“The pathogenesis of fibrosis in SSc has been the subject of several reviews published during the past 5 years”
Self-citationThe role of miRNA in inflammation and autoimmunity
Singh, R. P., Massachi, I., Manickavel, S., Singh, S., Rao, N. P., Hasan, S., Mc Curdy, D. K., Sharma, S., Wong, D., Hahn, B. H., et al. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.07.003 · Cited by 334
Metadata
- Authors
- Wei, J., Bhattacharyya, S., Tourtellotte, W. G., & Varga, J.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 10
- Issue
- 5
- Pages
- 267-275
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W2076665629
- Cited by
- 173
- References
- 11
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy. https://app.cochat.ai/papers/10.1016/j.autrev.2010.09.015
- The paper
- Wei, J., Bhattacharyya, S., Tourtellotte, W. G., & Varga, J. (2011). Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy. Autoimmunity Reviews. https://doi.org/10.1016/j.autrev.2010.09.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.